Additionally, L-leucine has been identified as a Sirt1 activator, acting on the AMPK-eNOS-Sirt1 pathway and capable of reversing mild NAFLD in preclinical mouse models (25). This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.